CRISPR

CRISPR1-sp5a

ID

ZDB-CRISPR-240325-6

Name

CRISPR1-sp5a

Previous Names

None

Target

sp5a (1)

Sequence

5' - AGGCATGGCTGGAGGGATGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "GGG" at the 3' end.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
x69	sp5a

Expression

Gene expression in Wild Types + CRISPR1-sp5a

No data available

Phenotype

Phenotype resulting from CRISPR1-sp5a

No data available

Phenotype of all Fish created by or utilizing CRISPR1-sp5a

Phenotype	Fish	Conditions	Figures
otic vesicle sp5l expression amount, ameliorated	sp5a^x69/x69 + MO2-sp5l	standard conditions	Fig. 10 from Tan et al., 2022
otic vesicle sp5l expression spatial pattern, ameliorated	sp5a^x69/x69 + MO2-sp5l	standard conditions	Fig. 10 from Tan et al., 2022
otic vesicle pax5 expression amount, ameliorated	sp5a^x69/x69 + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic placode atoh1a expression decreased distribution, abnormal	sp5a^x69/x69 + MO2-sp5l	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle pax5 expression spatial pattern, ameliorated	sp5a^x69/x69 + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle neurog1 expression decreased amount, abnormal	sp5a^x69/x69 + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic placode atoh1a expression decreased amount, abnormal	sp5a^x69/x69 + MO2-sp5l	standard conditions	Fig. 12 from Tan et al., 2022
statoacoustic (VIII) ganglion neuron ab2-isl labeling decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 11 from Tan et al., 2022
otic vesicle gsc expression decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
statoacoustic (VIII) ganglion neuron ab2-isl labeling decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic placode atoh1a expression decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle medial region sp5a expression decreased distribution, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic vesicle neurog1 expression amount, ameliorated	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic placode atoh1a expression decreased distribution, abnormal	sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle anterior region atoh1a expression increased distribution, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic vesicle medial region sp5a expression decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic vesicle medial region sp5l expression decreased distribution, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic vesicle medial region pax2a expression decreased distribution, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic vesicle medial region sp5l expression decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic vesicle medial region pax2a expression decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic vesicle neurog1 expression spatial pattern, ameliorated	sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 8 from Tan et al., 2022
otic vesicle sp5l expression spatial pattern, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic placode atoh1a expression decreased distribution, abnormal	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle pax5 expression amount, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle sp5l expression amount, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle pax5 expression spatial pattern, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle neurog1 expression spatial pattern, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic vesicle neurog1 expression amount, ameliorated	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 10 from Tan et al., 2022
otic placode atoh1a expression decreased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70 + MO1-sp5a + MO2-sp5l	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle hair cell GFP expression increased amount, abnormal	sp5a^x69/x69; sp5l^x70/x70; s356tTg/s356tTg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle pou3f3b expression decreased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle sp5a expression increased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle pax2a expression increased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
statoacoustic (VIII) ganglion neuron ab2-isl labeling decreased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle atoh1a expression increased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle sp5l expression increased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle sp5l expression increased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic placode atoh1a expression decreased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle pax2a expression increased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle sp5a expression increased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle gsc expression decreased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle pou3f3b expression decreased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle pax5 expression decreased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 11 from Tan et al., 2022
otic vesicle pou3f3b expression decreased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 11 from Tan et al., 2022
otic vesicle pax5 expression decreased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 11 from Tan et al., 2022
otic vesicle pax5 expression decreased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle pou3f3b expression decreased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 11 from Tan et al., 2022
statoacoustic (VIII) ganglion neuron ab2-isl labeling decreased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 11 from Tan et al., 2022
otic placode atoh1a expression decreased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	standard conditions	Fig. 12 from Tan et al., 2022
otic vesicle atoh1a expression increased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle pax5 expression decreased distribution, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle hair cell GFP expression increased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70; s356tTg/s356tTg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 11 from Tan et al., 2022
otic vesicle hair cell GFP expression increased amount, abnormal	pax2a^tu29a/tu29a; sp5a^x69/x69; sp5l^x70/x70; s356tTg/s356tTg	standard conditions	Fig. 11 from Tan et al., 2022

Citations